Artios

To add a bio or update company history, please click update information.

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

18 Nov 2025

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.

Artios

Life Sciences
Cambridge, United Kingdom
£90m
artios.com
Update Information

More venture news

BIOCAPTIVA
9 Mar 2026
BIOCAPTIVA secures £1.6m in funding led by Archangels for magnetic bead tech that prepares blood samples for liquid biopsy
EquityLife Sciences
LifeCellsNI
4 Mar 2026
LifeCellsNI secures £590k in pre-seed funding led by The AMP Angel Syndicate for regulated stem cell storage and biobanking facility
Pre-seedLife Sciences
3 Mar 2026
Antiverse secures £7m Series A led by Soulmates Ventures for AI-designed antibodies targeting undruggable diseases
Series ALife Sciences

Artios

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

More venture news

BIOCAPTIVA secures £1.6m in funding led by Archangels for magnetic bead tech that prepares blood samples for liquid biopsy

LifeCellsNI secures £590k in pre-seed funding led by The AMP Angel Syndicate for regulated stem cell storage and biobanking facility

Antiverse secures £7m Series A led by Soulmates Ventures for AI-designed antibodies targeting undruggable diseases